• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

September 30, 2019
Company Drug/Device Medical Condition Status
BioLineRx Ltd. AGI-134 solid tumors Phase 1/2a trial initiated enrolling subjects at 15 sites in the U.S., U.K. and Israel
Neuralstem Inc. NSI-566 chronic ischemic stroke Phase 2 trial initiated enrolling 22 subjects with sustained chronic motor deficits due to an ischemic stroke
Oragenics, Inc. AG013 severe oral mucositis Phase 2 trial initiated enrolling 200 subjects at 59 sites in the U.S. and Europe
ImaginAB, Inc. 89Zr-Df-IAB22M2C cancer Phase 2 trial initiated enrolling subjects with advanced and metastatic cancer at the O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham
Oncopeptides AB melflufen in combination with dexamethasone relapsed/refractory multiple myeloma (RRMM) Phase 2 trial initiated enrolling 150 subjects
Rigel Pharmaceuticals, Inc.
Kissei Pharmaceuticals Co., Ltd.
fostamatinib disodium hexahydrate chronic immune thrombocytopenia (ITP) Phase 3 study initiated enrolling adult subjects with ITP
Protalix BioTherapeutics, Inc.
Chiesi Farmaceutici S.p.A.
PRX 102 (pegunigalsidase alfa) Fabry disease with impaired renal function Phase 3 trial initiated enrolling subjects previously treated with an enzyme replacement therapy: agalsidase alfa or agalsidase beta
Ocular Therapeutix, Inc. DEXTENZA allergic conjunctivitis (AC) Phase 3 trial initiated enrolling 80 subjects
Annexon Biosciences ANX005 Guillain-Barré Syndrome (GBS) Fast Track approval granted by the FDA
Merck & Company PIFELTRO (in combination with other antiretroviral agents) HIV-1 in adult subjects who are virologically suppressed sNDA approval granted by the FDA
Merck & Company DELSTRIGO HIV-1 in adult subjects who are virologically suppressed sNDA approval granted by the FDA
Abiomed Impella 5.5 with SmartAssist minimally invasive forward flow heart pump residual myocardial function PMA approval granted by the FDA
Novo Nordisk Rybelsus (semaglutide) oral tablets type 2 diabetes Approval granted by the FDA
Exact Sciences Corp. Cologuard noninvasive colorectal cancer screening test for subjects ages 45 and older Approval granted by the FDA
Bavarian Nordic A/S Jynneos Smallpox and Monkeypox Vaccine, Live, Non-Replicating smallpox and monkeypox disease in adults 18 years of age and older Approval granted by the FDA

 

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing